European Primary Care Cardiovascular Society

Lipids

Three fascinating new strategies for lipid management

3' education - Dec. 14, 2023 - Karol Watson, MD, PhD

Benefit with bempedoic acid in reducing total incidence of MACE

3' education - Oct. 9, 2023 - Stephen Nicholls, MD

Regional differences in prescription of PCSK9i therapy across Europe

10' education - July 12, 2023 - Maciej Banach, MD, PhD

How to manage patients with elevated Lp(a)

3' education - June 26, 2023 - Florian Kronenberg, MD, PhD

Fitting in bempedoic acid in the arsenal of lipid-lowering therapies

3' education - Mar. 30, 2023 - Prof. Kausik Ray, MD

Lowering LDL-c and CV risk with new evidence-based non-statin treatment

3' education - Mar. 18, 2023 - Prof. Peter Libby, MD

A phase 3 trial with bempedoic acid: Strengths and limitations

3' education - Mar. 13, 2023 - Prof. Eugene Yang, MD

Bempedoic acid in CV outcomes trial in statin-intolerant patients

3' education - Mar. 10, 2023 - Prof. Steven Nissen, MD

Results for oral PCSK9 inhibitor promising to proceed to phase 3 trials

3' education - Mar. 9, 2023 - Prof. Christie Ballantyne, MD

What are the real effects of statins on muscle symptoms?

3' education - Sep. 12, 2022 - Prof. Colin Baigent, MD

A discussion on CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl

10' education - June 20, 2022 - Prof. Ulrich Laufs, MD, PhD, prof. Chris Packard, PhD and prof. Wouter Jukema, MD, PhD

Key findings of CV outcomes trials with icosapent ethyl

10' education - May 18, 2022 - Prof. Wouter Jukema, MD, PhD

Triglyceride-rich lipoproteins as residual CV risk in patients on statins

10' education - May 8, 2022 - Prof. Alberto Zambon, MD, PhD

Treating elevated Lp(a): beginning of an era

3' education - Apr. 16, 2022 - Steven Nissen, MD

After stopping therapy, continued benefit of statin treatment

5' education - July 12, 2021 - Jackie Bosch, PhD
Experts in dialogue - LDL-c goal attainment in high risk patients

Current barriers and challenges in achieving LDL-c goals

15' education - June 1, 2021 - Prof. Lale Tokgözoğlu, MD and prof. Kausik Ray, MD - Online CME
Experts in dialogue - LDL-c goal attainment in high risk patients

How are we doing: The gap between guideline LDL-c goals and current practice

15' education - May 11, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD
Experts in dialogue - LDL-c goal attainment in high risk patients

Benefit of LDL-c lowering: a proven case

15' education - May 4, 2021 - Prof. Kausik Ray, MD and prof. John Kastelein, MD, PhD

Treat also older adults to lower LDL-c

5' education - Jan. 19, 2021 - Prof. Børge Nordestgaard, MD

Majority side effects of statins also present with placebo

3' education - Dec. 3, 2020 - Prof. Darrel Francis, MD

To achieve lower LDL-c goals, combination therapy is necessary

3' education - Oct. 28, 2020 - Prof. Kausik Ray, MD

Reducing CV risk in diabetes in primary care

10' education - Oct. 27, 2020 - Prof. Richard Hobbs, MD
Lecture (panel discussion) 3 out of 3

What are the implications for practice? - A discussion on COVID-19, ACE2 and RAASi

10' education - May 14, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

A little closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 11, 2020 - Dirk Blom, PhD

Reduced CV risk with an intervention targeting identified barriers to care

3' education - Sep. 16, 2019 - Paris, France - Prof. J-D Schwalm

Lower LDL-c targets in the 2019 ESC/EAS Dyslipidaemia Guidelines: this is why

5' education - Sep. 9, 2019 - Prof. François Mach

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

Lowering remnants becomes more important, also in light of the obesity epidemic

3' education - June 19, 2019 - EAS 2019 - Prof. Børge Nordestgaard

EPCCS

3' education - Feb. 8, 2019

The cardiovascular challenge for primary care in diabetes

10' education - July 10, 2018 - Prof. Richard Hobbs - Oxford, UK

Diagnosis and management of children and adolescents with familial hypercholesterolemia

Literature - Jan. 15, 2024 - European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration - - Lancet. 2023

In an international cross-sectional registry study, classic diagnostic features of familial hypercholesterolemia were uncommon in individuals aged <18 years, and the diagnosis therefore relied on LDL-c levels or genetic confirmation. Most participants were not on lipid-lowering therapy.

Three fascinating new strategies for lipid management

3' education - Dec. 14, 2023 - Karol Watson, MD, PhD

AHA 2023 "This is such a fascinating time in lipid therapeutics," says Karol Watson. She substantiates this by summarizing three late-breaking science studies with VERVE-101, lepodisiran and recaticimab.

Elderly people also benefit from lipid-lowering therapy for primary prevention

Literature - Nov. 29, 2023 - Andersson NW, et al. - J Am Coll Cardiol. 2023

In a Danish cohort study, individuals aged ≥70 years achieved a similar relative risk reduction of major vascular events with lipid-lowering therapy for primary prevention of CVD as those aged <70 years.

Benefit with bempedoic acid in reducing total incidence of MACE

3' education - Oct. 9, 2023 - Stephen Nicholls, MD
**ESC Congress 2023** Stephen Nicholls shares the results of the total events analysis of the CLEAR Outcomes trial. He compares the hazard ratios of the first event and total events analyses and explains the implications of these results.

ESC Congress 2023 Stephen Nicholls shares the results of the total events analysis of the CLEAR Outcomes trial. He compares the hazard ratios of the first event and total events analyses and explains the implications of these results.

Regional differences in prescription of PCSK9i therapy across Europe

10' education - July 12, 2023 - Maciej Banach, MD, PhD
Maciej Banach presents the results of a subanalysis of the ODYSSEY APPRISE study. In this analysis differences in physicans’ behavior and factors influencing the intensity of PCSK9i therapy with alirocumab were determined in Central and Eastern Europe vs. other European countries plus Canada.

Maciej Banach presents the results of a subanalysis of the ODYSSEY APPRISE study. In this analysis differences in physicans’ behavior and factors influencing the intensity of PCSK9i therapy with alirocumab were determined in Central and Eastern Europe vs. other European countries plus Canada.

How to manage patients with elevated Lp(a)

3' education - June 26, 2023 - Florian Kronenberg, MD, PhD
**EAS Congress 2023** Florian Kronenberg discusses the EAS consensus statement on Lp(a) in ASCVD and aortic stenosis, which contains recommendations for testing of Lp(a), risk estimation, and management of patients with elevated Lp(a) levels.

EAS Congress 2023 Florian Kronenberg discusses the EAS consensus statement on Lp(a) in ASCVD and aortic stenosis, which contains recommendations for testing of Lp(a), risk estimation, and management of patients with elevated Lp(a) levels.

Lower achieved LDL-c levels associated with lower CV risk in ASCVD

Literature - June 23, 2023 - Gaba P, et al. - Circulation. 2023

A secondary analysis of the FOURIER-OLE trial investigated what the optimal achieved LDL-c levels are with PCSK9i in patients with ASCVD, with regards to long-term cardiovascular and safety outcomes.

Majority of patients with high or very high CV risk between 2020-2021 still fail to achieve LDL-c goals

Literature - June 21, 2023 - Ray KK, et al. - Lancet Reg Health Eur. 2023

In 2019, the ESC/EAS recommended more stringent LDL-c goals, and a greater use of combination therapies. In the SANTORINI study was investigated whether the treatment landscape has improved since then.

Moderate-intensity statin plus ezetimibe as an alternative to high-intensity statin in ASCVD patients ≥75 years

Literature - June 19, 2023 - Lee SH, et al. - J Am Coll Cardiol. 2023

In an age-stratified post-hoc analysis of the RACING trial, combination therapy with a moderate-intensity statin plus ezetimibe showed similar CV benefits as high-intensity statin monotherapy in elderly ASCVD patients, regardless of age group.

PCSK9i reduces coronary plaque burden in asymptomatic patients with FH

Literature - June 19, 2023 - Pérez de Isla L, et al. - Circulation. 2023

In the single-arm ARCHITECT study, the authors demonstrated that the addition of alirocumab to statin therapy in asymptomatic patients with FH reduces coronary plaque burden and promotes plaque stabilization.

Data from clinical care: less LDL-c reduction with PCSK9 antibodies in women than men

Literature - June 15, 2023 - Galema-Boers AMH, et al. - Atherosclerosis. 2023

In a Dutch, real-world study of patients at very high CVD risk on maximum-tolerated lipid-lowering therapy, PCSK9 antibodies resulted in less relative LDL-c reduction at 6 months in women compared with men. Of note, women did have higher baseline LDL-c levels.

Effect of optimal risk factor management on recurrent ASCVD risk

Literature - Apr. 4, 2023 - Van Trier TJ, et al. - Eur J Prev Cardiol. 2023

A pooled analysis of patients with established ASCVD showed a 10-year risk of recurrent ASCVD events of 20% and a lifetime risk of 54%. Theoretically, optimization of both lifestyle and medications could reduce both risks and add 7.3 event-free years.